IDE and early-onset autosomal dominant Alzheimer disease: Because reduced IDE function has been implicated in the pathogenesis of both T2DM and Alzheimer disease [142], these studies lend support the notion that pharmacological upregulation of IDE might represent viable therapeutic strategies for the treatment of both diseases.